{"ticker": {"uuid": "c3d1ab5c-d74a-49c7-a7f9-380f2167dfd4", "symbol": "1672", "name": "Ascletis Pharma Inc.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T05:33:24+00:00", "published_display": "06 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B (01672.HK) This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AJBVV95cUxPTU0zRnN5SzRsVUJrdkh2d1ZwLW9sRVd6ME1iTGVRcWc3UVhfLW5PUDh4dTQ0aGdEMERQc0RGUUhhdTJ5a1MxLWFHNGx2aVNHUjU0blRZUEVsbW9UNW12UnVBWEFuNnNBRmU5ZEdxUzlBem80WS1UeUh6c3l6MGNITlBVMmdQNGphQjlyenVTaWo0dDdWY3AwTWRfVTBIZXJGcjN2SXZ4OWpHem9oNG5PVEk0T0NiZ24xQmFmenAtcm1pcnpSNGViUWl4YjluUURKR1lEM2FGbE1QbmEzeXJmckNhT3RCY0djWkVCdlVXc1BfUjNzcm05Q29uRFlPaTVibVFncldwTGFvblFXbjcwTlhZV0drMTRhbXNIbFhreUNqeG82VC1iaFhDcDdQYXc2UjJ4eDVUNE01bkdHcDNucHN1eXFQNG9mSjltNk9GU3BhQ0hLcy14a0ZFSUdHNWVhZ2dQXw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Ascletis Pharma Insider Has Reduced Their Stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNLWNPYWxQWE1JRnFjRmtXSWJFYlBQYjJUdm94MzhYQ0dnZHZzSFBuVnFFVlg0REhzVi1sa2Nsa3JVWjFzVjdLdDItS2wzblJTUzgzdWpBU2pBVHZIcTdIc0x6WUp1LUNpT0lBM3JpVnB0M2NveG5xY0U4Nk1LREdOVXJpaWxXQ3JRMEtUaUxrcnZpRTRKeURyckdpZ1A2X212eExnd0hmR1NhN3FCQlJrcG5qQmdYSWo3aEN1ODQ0UkV1S1NQcGVObVdfOGNUUTd1dGdqeG15VG5HRlN00gHiAUFVX3lxTE9qOTE5UWh1TEw0ODBVTzU0M05lYnNtYk9paEJUUEhaR2Q1RHV3V1NMM3BpQWNMTXROU21ESG95bVEyTmFsUnpaeUtRTkd2QnlrUnhidk5TTUlWNG9SS21YQlNiWU1VMlZaZ0tzbWVPaURabFJrdUp1TXBNZVFHbE1EVTZibDNwSUZ6eHh0YlVnMmdmOHM3bGp5cmU1dlV6a1VZT0ZFcl9KU0tEdmpwdG5ob1duOGhMaW5iMklFOWFYT2J2eUdqN0YwTUZNOEV0bDVSTDc4MHhtZXhwVDc1aEMyUVE?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ascentage Pharma Group International\u2019s Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYjk2WWd1YXZWeXYyZFNjTVc0Y3htdnJsRVJGTWRzbzZYQVk0dUlMOWF2WHJEN0tlLTd4d25UWHBEVGhEQXV5c3NIVlIzWER5SHk0ZkJxWFBBVnd4c3VKWER3ajRfN3RvNjdZanMwRk14b1VjTHhTMWlrN1djWHZ1ZGRySGhGM3psU2ZRMXdWUURiV0poMUE3dV9LY1Z2ekRlTEJiY1d4MC1MZw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNbEFfZ1d0RUl6eE1ZazlaUGJDUzNBdUJDWGZxSFVheXo0ZVlvcUF3Y25hZ3NuRElWOXlfclVzclpmNWppYWZQWTdwMUtsZkV2ZHpXNlo5b2JiZ1pNT3VQOUkwOFFKeUJKaFB4UG02dTlMN0FzaUhzeU13d0FwSlFleFI4SjlTTEdyNlhtSnNNaVRmOGFBRVVsN2l6WHhhMVRsaUMwbmJTQlljNC1EeGxmNXZPZldHS1RhNEhsSUlfcW45dUZhZjB5b19ZZXN0d3VuTjYwbXd3ajZDT0pRTVVOQVFn?oc=5", "source_name": "BioSpace", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma\u2019s ASC36 Obesity Move Meets Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZUFidVo5bDNyaUN3V3pPem1kTXY2Z2xVcThKaDlvZWotcHJpT05BMTN5UGFfeTFmVDI5N1JoZXl2S2RvaWtNOVhmV3pEdlNqMDRwUURlaE12TXRDVzF2WGtrNVRRX2lOVmFoVVhSSXg4SmpldWQ1N0dtZHRNVG42dXBvNWZGS1k?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis raises $107M to advance oral GLP-1 to phase III trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOLVoxenpZTHJRbHlINkdZZktSZVluOGU5amVXNDFvOG9zbVR2aVRfWE0tLUs1Nm5uWHI3MXhzdHIxQXVLelVKN21kdGd5dU5SRll3dTlsQlBSSnBSRGRhV1RMN2JKcmN1RjNJZG4wa0FvaTFqdTJ1SnpQbkw0Z25jSUJaZkFSUTM4ZUlXbG5HZXAtdERGTTBVOG94ZHRqRC1HTUpzc0t3?oc=5", "source_name": "BioWorld News", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRIEF: Ascletis raises $107 million to fund obesity drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUHdqbzNHWHcwQkxDcmFyczZ6OVQxS0FOdVlrdzBXTDhwelJDZDZnbVFyYnBReXRic2ZVbHFZSGFxNldSTHFjNTRuQjI4dnJxbU1xR0pvTTN0TS1MTG5tbXpXZFBWZDFPMDEwN2puTGVEOUxSa2FWbU9FcWthckttWW8zUUJoamlfRDlB?oc=5", "source_name": "thebambooworks.com", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek\u00ae 2025", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Manila Times", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma Inc. (HKEX: 1672) is a Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5yWHFjWGtNY3M1dGYzVzV5SklZWFJsRWtodDBOaUN3d3A2OThaZEJweGVnRzN2UjUtaGxWZ3Ruem1XY3JZeUs2U0xHVjN2RVZrUXh4TFhsbURuX09LcHBjRVo3YWV0eXhzRkZUQlpWaEJtNzR3bVdCNGNB?oc=5", "source_name": "livetradingnews.com", "published_at": "2021-05-26T07:00:00+00:00", "published_display": "26 May 2021 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Ascletis Pharma CEO Discusses Hong Kong IPO, Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTmpuVjBkWXcyX2Q5U1dYVWQzYmtiRkUzaGdKUXpjOV9Sc25PVE9wRFJBci1tX3N4Zm85WGtMSEpMVlFXUmVJeXlkZVVLUlNLTXE1X2plSl9BZDNkeWFQcUc1WWNwU1dKajlGZnhHdTRnYUI2WktmVHhIRlVIWUJfOUdKVzlCdldISGRNWnBjajU4dnpRZkc2a3I4ZE1UWHo0Q3prVnVvTy10QQ?oc=5", "source_name": "Bloomberg.com", "published_at": "2018-08-01T07:00:00+00:00", "published_display": "01 Aug 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Is First Biotech Firm With IPO in Hong Kong After Rules Eased", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQc2VNLU4zWlFJUXBPRTJEd0sydWNPTUx5OUFzTVFYNXR5MnZPZTF2Qkc2dFBjLVFmb01RTDVEOE9VN3hsaXJKX1g4b3JyTV83eEpnRnAtNTNHemZSWFQwaUswbGdWd3ZRMWdsMkVZalpWalJXdkl3aWktSGRKcW5OSVZBNjlvN09scjlqN3dQVmtaSmQ4bWw3ZkJvRGxOdVR1bVNFZ3FYYjMwYUFQZURrMXd2eXdRV0tyZjRMTmNtUE1sOXc?oc=5", "source_name": "Caixin Global", "published_at": "2018-07-20T07:00:00+00:00", "published_display": "20 Jul 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-06T05:33:24+00:00", "published_display": "06 Jul 2026 05:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B (01672.HK) This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AJBVV95cUxPTU0zRnN5SzRsVUJrdkh2d1ZwLW9sRVd6ME1iTGVRcWc3UVhfLW5PUDh4dTQ0aGdEMERQc0RGUUhhdTJ5a1MxLWFHNGx2aVNHUjU0blRZUEVsbW9UNW12UnVBWEFuNnNBRmU5ZEdxUzlBem80WS1UeUh6c3l6MGNITlBVMmdQNGphQjlyenVTaWo0dDdWY3AwTWRfVTBIZXJGcjN2SXZ4OWpHem9oNG5PVEk0T0NiZ24xQmFmenAtcm1pcnpSNGViUWl4YjluUURKR1lEM2FGbE1QbmEzeXJmckNhT3RCY0djWkVCdlVXc1BfUjNzcm05Q29uRFlPaTVibVFncldwTGFvblFXbjcwTlhZV0drMTRhbXNIbFhreUNqeG82VC1iaFhDcDdQYXc2UjJ4eDVUNE01bkdHcDNucHN1eXFQNG9mSjltNk9GU3BhQ0hLcy14a0ZFSUdHNWVhZ2dQXw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Ascletis Pharma Insider Has Reduced Their Stake", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ascentage Pharma Group International\u2019s Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYjk2WWd1YXZWeXYyZFNjTVc0Y3htdnJsRVJGTWRzbzZYQVk0dUlMOWF2WHJEN0tlLTd4d25UWHBEVGhEQXV5c3NIVlIzWER5SHk0ZkJxWFBBVnd4c3VKWER3ajRfN3RvNjdZanMwRk14b1VjTHhTMWlrN1djWHZ1ZGRySGhGM3psU2ZRMXdWUURiV0poMUE3dV9LY1Z2ekRlTEJiY1d4MC1MZw?oc=5", "source_name": "Market source", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNbEFfZ1d0RUl6eE1ZazlaUGJDUzNBdUJDWGZxSFVheXo0ZVlvcUF3Y25hZ3NuRElWOXlfclVzclpmNWppYWZQWTdwMUtsZkV2ZHpXNlo5b2JiZ1pNT3VQOUkwOFFKeUJKaFB4UG02dTlMN0FzaUhzeU13d0FwSlFleFI4SjlTTEdyNlhtSnNNaVRmOGFBRVVsN2l6WHhhMVRsaUMwbmJTQlljNC1EeGxmNXZPZldHS1RhNEhsSUlfcW45dUZhZjB5b19ZZXN0d3VuTjYwbXd3ajZDT0pRTVVOQVFn?oc=5", "source_name": "BioSpace", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma\u2019s ASC36 Obesity Move Meets Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNZUFidVo5bDNyaUN3V3pPem1kTXY2Z2xVcThKaDlvZWotcHJpT05BMTN5UGFfeTFmVDI5N1JoZXl2S2RvaWtNOVhmV3pEdlNqMDRwUURlaE12TXRDVzF2WGtrNVRRX2lOVmFoVVhSSXg4SmpldWQ1N0dtZHRNVG42dXBvNWZGS1k?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis raises $107M to advance oral GLP-1 to phase III trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOLVoxenpZTHJRbHlINkdZZktSZVluOGU5amVXNDFvOG9zbVR2aVRfWE0tLUs1Nm5uWHI3MXhzdHIxQXVLelVKN21kdGd5dU5SRll3dTlsQlBSSnBSRGRhV1RMN2JKcmN1RjNJZG4wa0FvaTFqdTJ1SnpQbkw0Z25jSUJaZkFSUTM4ZUlXbG5HZXAtdERGTTBVOG94ZHRqRC1HTUpzc0t3?oc=5", "source_name": "BioWorld News", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRIEF: Ascletis raises $107 million to fund obesity drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUHdqbzNHWHcwQkxDcmFyczZ6OVQxS0FOdVlrdzBXTDhwelJDZDZnbVFyYnBReXRic2ZVbHFZSGFxNldSTHFjNTRuQjI4dnJxbU1xR0pvTTN0TS1MTG5tbXpXZFBWZDFPMDEwN2puTGVEOUxSa2FWbU9FcWthckttWW8zUUJoamlfRDlB?oc=5", "source_name": "thebambooworks.com", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek\u00ae 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowJBVV95cUxQU09UUlczSVhUOHBkSi1adkxUZnpvcnBOeTdmTWxCV1ZrZDVBQ05jVkRBTGY3MnJFWVhsYng1N21GblRlVC1WMXdJUndkRUhuYmZ4dk5QeDgzWUV3OTdUajRLOGVlS3FlbWstYTBVSG52VTcxZ2FPZ0ZoMXFtX21LY1h0a0ZJeW04VTNXSEdBc2toZ0YyY3pRLVZfWGJUbldEaTdaRHZtQTkyUjBkMGtrOGYxZGVPRGs2dFBJU0VKUEVwQXdqMDVWMDNrX2tFQzY0dHIxRVB4RUR0cHByMzg5N0NuYW94VVN4NFZSVW9DWEZPYVU1QWVUZTVPVDdjM2c4M0szY29qUEpjbEVYc2xHZmpDVWU0Rm5ZSUpJQzl5Zm9KcDjSAagCQVVfeXFMUF9USHdOZWNrbzRMRmszUmg1ampUcjRHMmpJelBCOVhzSGpSREJNWjZOUjAxdkRNMGVCMlhiR2R3UUx6OVRBdmZ2UEt2aWszOWlQY1M4eG4tMUhWWW9TOXdhczd4UnJBRnF2bDhTLXZ3MlVIVVBxT2J3VlllREVhb096TFpNUG1qWEp2bDFwdDhlS2F1MEoyN0h2M2p5NURIcWRGSHBfbF9McDNmSUtPNkhTeWRpYThpbzFQMU4yWTBwcXJSQzVlclk5OUtlQnZPRk92b3FPbkZQeUlvSkZYYUpuMG5IcHFpNzBjRjBjckpSWGZLcTZDbXFQdExCN2N6OXFfWVE5VzB0TFY0dFhudFlnYTZmcUZ4Q0h0N1Rra2ozcjB4Zm95UXE?oc=5", "source_name": "The Manila Times", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Pharma Inc. (HKEX: 1672) is a Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE5yWHFjWGtNY3M1dGYzVzV5SklZWFJsRWtodDBOaUN3d3A2OThaZEJweGVnRzN2UjUtaGxWZ3Ruem1XY3JZeUs2U0xHVjN2RVZrUXh4TFhsbURuX09LcHBjRVo3YWV0eXhzRkZUQlpWaEJtNzR3bVdCNGNB?oc=5", "source_name": "livetradingnews.com", "published_at": "2021-05-26T07:00:00+00:00", "published_display": "26 May 2021 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Ascletis Pharma CEO Discusses Hong Kong IPO, Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTmpuVjBkWXcyX2Q5U1dYVWQzYmtiRkUzaGdKUXpjOV9Sc25PVE9wRFJBci1tX3N4Zm85WGtMSEpMVlFXUmVJeXlkZVVLUlNLTXE1X2plSl9BZDNkeWFQcUc1WWNwU1dKajlGZnhHdTRnYUI2WktmVHhIRlVIWUJfOUdKVzlCdldISGRNWnBjajU4dnpRZkc2a3I4ZE1UWHo0Q3prVnVvTy10QQ?oc=5", "source_name": "Bloomberg.com", "published_at": "2018-08-01T07:00:00+00:00", "published_display": "01 Aug 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascletis Is First Biotech Firm With IPO in Hong Kong After Rules Eased", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQc2VNLU4zWlFJUXBPRTJEd0sydWNPTUx5OUFzTVFYNXR5MnZPZTF2Qkc2dFBjLVFmb01RTDVEOE9VN3hsaXJKX1g4b3JyTV83eEpnRnAtNTNHemZSWFQwaUswbGdWd3ZRMWdsMkVZalpWalJXdkl3aWktSGRKcW5OSVZBNjlvN09scjlqN3dQVmtaSmQ4bWw3ZkJvRGxOdVR1bVNFZ3FYYjMwYUFQZURrMXd2eXdRV0tyZjRMTmNtUE1sOXc?oc=5", "source_name": "Caixin Global", "published_at": "2018-07-20T07:00:00+00:00", "published_display": "20 Jul 2018 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 14, "sentiment_summary": {"positive": 7, "negative": 0, "neutral": 7, "score": 58, "total": 14, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 5.85, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}], "positive_events": 7, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 11.17, "latest_week": "2026-07-10", "one_week_move": -3.2, "four_week_move": 11.5, "twelve_week_move": -39.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.955127, "market_dynamics_buy_signal": false, "relative_strength": -11.512524, "fair_value_gap": 75.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 41.7508, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, +11.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "simplywall.st", "count": 4}, {"label": "Market source", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "BioSpace", "count": 1}, {"label": "BioWorld News", "count": 1}, {"label": "thebambooworks.com", "count": 1}, {"label": "The Manila Times", "count": 1}, {"label": "livetradingnews.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 14}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 10}, {"label": "Deals and strategy", "count": 2}, {"label": "Earnings", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "14", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.2% over one week, +11.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?"}], "updated_at": "2026-07-18T01:21:16.490805+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}